Mahmoud Mahmoud Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahmoud Mahmoud Ibrahim has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Mazen Amin
Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 shared publications - Basel Abdelazeem
Department of Cardiology West Virginia University Morgantown West Virginia USA
2 shared publications - Ahmed Almahdy Mohamed
Cardiovascular Department, University of Minnesota Twin Cities
1 shared publication Amith Seri
McLaren Flint Hospital
1 shared publication- Azeem Latib
Montefiore Medical Center
1 shared publication - Basma Ehab Amer
Benha University
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (4) , 669-681
Efficacy and safety of exercise for hypertrophic cardiomyopathy: a systematic review and meta-analysis
Patients with hypertrophic cardiomyopathy (HCM) are generally restricted from exercising. We aimed to investigate the effects of exercise on cardiorespiratory fitness, cardiac structure, cardiac function, and clinical safety for patients with HCM. We performed a systematic review and meta-analysis by searching PubMed, Web of Science, Scopus, Embase, and CENTRAL up to April 2025. Dichotomous outcomes were pooled using risk ratios (RRs), while continuous outcomes were pooled using mean differences (MDs) or standardized mean differences (SMDs), all with 95% confidence intervals (CIs), using R version 4.3.1. With the inclusion of seven studies—three randomized controlled trials and four observational studies—our cohort comprised 9702 patients. Compared to the control group, exercise was significantly associated with increased cardiorespiratory fitness (peak oxygen consumption [peak VO2] (mL∙kg−1∙min−1) (MD: 1.78; 95% CI [0.98, 2.59]; P < 0.01) and VO2 at an anaerobic threshold (mL∙kg−1∙min−1) (MD: 1.27; 95% CI [0.34, 2.20]; P < 0.01), reduced body mass index (kg/m2) (MD: −0.67; 95% CI [−1.17, −0.18]; P < 0.01), reduced left ventricular wall thickness (mm) measured by echocardiography (MD: −0.56; 95% CI [−1.01, −0.11]; P = 0.01), increased quality of life physical factor (SMD: 0.66; 95% CI [0.34, 0.97]; P < 0.01), and decreased incidence of all-cause mortality (RR: 0.71; 95% CI [0.60, 0.85]; P < 0.01). This study suggests that structured exercise interventions are safe and associated with improvements in cardiorespiratory fitness, left ventricular wall thickness, body mass index, and quality of life physical factor in patients with HCM, without increasing the risk of arrhythmias. Although a lower mortality rate was observed, this finding was mainly driven by observational studies and should therefore be interpreted with caution. Larger randomized controlled trials are needed to confirm these findings.
- 18 May 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (4) , 669-681
Open AccessEfficacy and safety of exercise for hypertrophic cardiomyopathy: a systematic review and meta-analysis
Patients with hypertrophic cardiomyopathy (HCM) are generally restricted from exercising. We aimed to investigate the effects of exercise on cardiorespiratory fitness, cardiac structure, cardiac function, and clinical safety for patients with HCM. We performed a systematic review and meta-analysis by searching PubMed, Web of Science, Scopus, Embase, and CENTRAL up to April 2025. Dichotomous outcomes were pooled using risk ratios (RRs), while continuous outcomes were pooled using mean differences (MDs) or standardized mean differences (SMDs), all with 95% confidence intervals (CIs), using R version 4.3.1. With the inclusion of seven studies—three randomized controlled trials and four observational studies—our cohort comprised 9702 patients. Compared to the control group, exercise was significantly associated with increased cardiorespiratory fitness (peak oxygen consumption [peak VO2] (mL∙kg−1∙min−1) (MD: 1.78; 95% CI [0.98, 2.59]; P < 0.01) and VO2 at an anaerobic threshold (mL∙kg−1∙min−1) (MD: 1.27; 95% CI [0.34, 2.20]; P < 0.01), reduced body mass index (kg/m2) (MD: −0.67; 95% CI [−1.17, −0.18]; P < 0.01), reduced left ventricular wall thickness (mm) measured by echocardiography (MD: −0.56; 95% CI [−1.01, −0.11]; P = 0.01), increased quality of life physical factor (SMD: 0.66; 95% CI [0.34, 0.97]; P < 0.01), and decreased incidence of all-cause mortality (RR: 0.71; 95% CI [0.60, 0.85]; P < 0.01). This study suggests that structured exercise interventions are safe and associated with improvements in cardiorespiratory fitness, left ventricular wall thickness, body mass index, and quality of life physical factor in patients with HCM, without increasing the risk of arrhythmias. Although a lower mortality rate was observed, this finding was mainly driven by observational studies and should therefore be interpreted with caution. Larger randomized controlled trials are needed to confirm these findings.
- Open Access
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e043791
Preoperative Colchicine and Conduction Disturbances After Transcatheter Aortic Valve Implantation: A US Retrospective Cohort Analysis
Background: Conduction disturbances are frequent complications following transcatheter aortic valve intervention (TAVI), partially driven by inflammation. The anti‐inflammatory role of colchicine on these disorders post TAVI has not been studied yet. Therefore, we investigated the association between preoperative colchicine use and conduction disturbances after TAVI. Methods: We used the TriNetX platform, a data repository of health record data from health care organizations in the United States, to identify patients receiving any colchicine prescription within 3 months before their first TAVI and compared them to propensity score matched patients never exposed to colchicine up to 1 year after the procedure. Primary outcomes included new‐onset or worsening atrioventricular or left bundle‐branch block (LBBB) and heart block (HB) postoperatively. Outcomes were assessed within 1 and 6 months after TAVI with an E‐sensitivity analysis assessing the impact of unmeasured confounders. Results: Of 52 860 patients, 705 were on preoperative colchicine. After matching, each group included 702 patients. Colchicine was associated with a statistically significant reduction of new‐onset or worsening atrioventricular/left bundle‐branch block and heart block post TAVI at 1 month (relative risk [RR], 0.867 [95% CI, 0.756–0.994], P =0.041; RR, 0.887 [95% CI, 0.788–0.999], P =0.047, respectively) but not at 6 months (RR, 0.886 [95% CI, 0.779–1.077], P =0.064; RR, 0.913 [95% CI, 0.817–1.020], P =0.109, respectively). The E‐value was >1.5 for the statistically significant outcomes. Conclusions: Preoperative colchicine was associated with a lower incidence of new‐onset or worsening atrioventricular/left bundle‐branch block and heart block after TAVI at 1 month. However, no significant difference was observed at 6 months. Future prospective studies are needed to evaluate the definitive role of colchicine in improving TAVI outcomes.
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e043791
Open AccessPreoperative Colchicine and Conduction Disturbances After Transcatheter Aortic Valve Implantation: A US Retrospective Cohort Analysis
Background: Conduction disturbances are frequent complications following transcatheter aortic valve intervention (TAVI), partially driven by inflammation. The anti‐inflammatory role of colchicine on these disorders post TAVI has not been studied yet. Therefore, we investigated the association between preoperative colchicine use and conduction disturbances after TAVI. Methods: We used the TriNetX platform, a data repository of health record data from health care organizations in the United States, to identify patients receiving any colchicine prescription within 3 months before their first TAVI and compared them to propensity score matched patients never exposed to colchicine up to 1 year after the procedure. Primary outcomes included new‐onset or worsening atrioventricular or left bundle‐branch block (LBBB) and heart block (HB) postoperatively. Outcomes were assessed within 1 and 6 months after TAVI with an E‐sensitivity analysis assessing the impact of unmeasured confounders. Results: Of 52 860 patients, 705 were on preoperative colchicine. After matching, each group included 702 patients. Colchicine was associated with a statistically significant reduction of new‐onset or worsening atrioventricular/left bundle‐branch block and heart block post TAVI at 1 month (relative risk [RR], 0.867 [95% CI, 0.756–0.994], P =0.041; RR, 0.887 [95% CI, 0.788–0.999], P =0.047, respectively) but not at 6 months (RR, 0.886 [95% CI, 0.779–1.077], P =0.064; RR, 0.913 [95% CI, 0.817–1.020], P =0.109, respectively). The E‐value was >1.5 for the statistically significant outcomes. Conclusions: Preoperative colchicine was associated with a lower incidence of new‐onset or worsening atrioventricular/left bundle‐branch block and heart block after TAVI at 1 month. However, no significant difference was observed at 6 months. Future prospective studies are needed to evaluate the definitive role of colchicine in improving TAVI outcomes.
- Open Access
- 11 April 2023
- Published by Wiley
Left Main Coronary Spasm During Cryoballoon Ablation for Atrial Fibrillation: A Case Report and Literature Review
Well known adverse effects of cryoablation are phrenic nerve and esophageal injury. (1, 2) However, there is very little literature about coronary artery spasm (CAS), a life-threatening complication of cryoablation. We report a case of a 68-year-old Caucasian female, who developed left main coronary spasm (CAS) with significant hemodynamic compromise during cryoablation. Although rare, this complication can be life threatening. Prompt recognition and appropriate intervention is critical for good patient outcome.
- 11 April 2023
- Published by Wiley
Open AccessLeft Main Coronary Spasm During Cryoballoon Ablation for Atrial Fibrillation: A Case Report and Literature Review
Well known adverse effects of cryoablation are phrenic nerve and esophageal injury. (1, 2) However, there is very little literature about coronary artery spasm (CAS), a life-threatening complication of cryoablation. We report a case of a 68-year-old Caucasian female, who developed left main coronary spasm (CAS) with significant hemodynamic compromise during cryoablation. Although rare, this complication can be life threatening. Prompt recognition and appropriate intervention is critical for good patient outcome.